Molecular Biomarkers & Diagnosis

Federica Cattina

Publications

• Short Communication
  Favourable/Intermediate ELN-Risk Acute Myeloid Leukemia to Transplant or Not to Transplant First-Line?
  Author(s): Michele Malagola, Federica Cattina, Valeria Cancelli, Benedetta Rambaldi, Enrico Morello, Nicola Polverelli, Alesssandro Turra, Simona Bernardi and Domenico RussoMichele Malagola, Federica Cattina, Valeria Cancelli, Benedetta Rambaldi, Enrico Morello, Nicola Polverelli, Alesssandro Turra, Simona Bernardi and Domenico Russo
  
  Favourable/intermediate ELN-risk acute myeloid leukemias (AMLs) (e.g. those harboring t(8;21) or inv(16) or NPM1A mutations or CEBP-alpha bi-allelic mutations) account for 30% to 50% of all newly diagnosed AMLs [1,2]. In this setting, conventional induction treatments may induce complete remission (CR) in up to 70% to 80%, but relapses still occur in 40% to 50% of cases and, at the end, no more than 30% to 40% of patients can be cured. Therefore, the optimization of post- remission therapy represents the greatest challenge in the treatment of favourable/intermediate-I ELN-risk AML... Read More»
  DOI: 10.4172/2155-9929.1000344

  Abstract PDF